Autolus Therapeutics plc is a clinical-stage biopharmaceutical company that develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1) for adult ALL, AUTO1/22 for pediatric ALL, AUTO4 for peripheral T-cell lymphoma, AUTO6NG for neuroblastoma, and AUTO8 for multiple myeloma. It also focuses on developing AUTO5 for peripheral T-cell lymphoma.

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. 

Blackstone Group

4BIO Capital

PPF Group

Woodford Investment Management

Arix Bioscience

Cormorant Asset Management

Google Ventures

Nextech Invest

Syncona Partners LLP

UCLB

Autolus Therapeutics

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics plc

COM:AUTOLUS

Autolus Therapeutics plc

Last Close

2.84

22/11 21:00

Market Cap

609.42M

Beta: -

Volume Today

1.60M

Avg: -

Analysis Not Available